The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly

Abstract

After lifestyle and behavioral measures to control overactive bladder, the mainstay of pharmacological treatment is the use of antimuscarinic therapy. Overactive bladder predominantly affects older people, who experience the most severe disease, and are also at a greater risk of side effects from antimuscarinic therapy. Thus it is imperative that data are available on the efficacy and tolerability of this group of drugs when used in older people. This article reviews the pathophysiology of the condition, its effect on the elderly and the evidence for the use of extended release tolterodine in the elderly using data from placebo and active drug controlled studies.

Keywords:

• overactive bladder
• tolterodine
• urgency incontinence

Disclosures

Dr Wagg has received funds for research, lectures and consultancy from Pfizer, Astellas and Ferring. No financial assistance was given for the production of this paper.